PeptideStack
5.2kquestions
20kanswers
220users

Does hair thinning at week eight of survodutide usually resolve without a dose change?

Asked 23 Sept 2025Modified 10 months agoViewed 6.5k times
24

Stated plainly: hair thinning · eight · survodutide.

This is a procedural question rather than a theoretical one, and I would like the procedure rather than the theory.

What I have done so far is read the label documentation where it exists and the two pharmacopoeial monographs that are publicly available, which cover the licensed presentation and say nothing about a research one.

What is the correct sequence, and where is the step that people usually skip?

gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

346 questions
shareeditfollowflag
EM
askedeoin_mcgarry16k1823 Sept 2025
Two of us worked through this independently and arrived here, so it is at least reproducible. – Dr_Priya_Raghunathan 2 months ago
Worth adding that the method section is where the answer usually is. – a_lindgren 23 days ago
add a comment

2 Answers

Accepted answer first, then by votes
97

Accepted answer

Timing is the most useful diagnostic feature here and it is the one most often omitted from the question.

Fatigue attribution is a subtraction problem. Take out the energy deficit, the dehydration, the electrolyte shortfall and the poor sleep, and what remains attributable to the drug in the trials was modest — placebo-arm fatigue rates were within a few points of active-arm rates in most of the programme. The corollary is that the fixable causes are usually the actual causes.

Gastrointestinal adverse events, indicative pooled rates

EventActive armPlacebo armTiming
Nausea40–45 %15–20 %Peaks 1–2 wk after each step
Vomiting15–25 %5–8 %Follows nausea
Diarrhoea20–30 %10–15 %Early, variable
Constipation20–25 %8–12 %Later onset, persistent
Discontinuation for GI events4–7 %1–2 %Mostly during escalation

Ranges span agents and doses; read the specific prescribing information for a specific figure.

Nausea incidence in the pivotal trials runs to roughly 40 to 45 per cent at the higher doses against 15 to 20 per cent on placebo, with vomiting at roughly 15 to 25 per cent against 5 to 8 per cent. Discontinuation specifically attributable to gastrointestinal adverse events was in the range of 4 to 7 per cent. Those are the numbers to hold in mind when someone describes their experience as unusual.

SURMOUNT-1 reported gastrointestinal events as the most frequent adverse events, mostly mild to moderate and mostly during escalation, with discontinuation for adverse events in the single digits per cent[1].

One qualification — reported incidence in a monitored trial population is a lower bound on what happens in an unmonitored one, because trial participants were escalated to protocol and supported through it.

A symptom diary with dates against dose steps answers most of these questions without anyone needing to guess.

edited 25 Sept 2025 by deamidation_watch — added the citation requested in comments

shareimprove this answerflag
DW
answered · accepteddeamidation_watch43k3824 Sept 2025
6Small correction: the units in the third paragraph should be micrograms, not milligrams. – bufferline42 8 months ago
5Do you have a reference for the last claim? Not disputing it, just want to read it. – rosa_mendieta 7 months ago
add a comment
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
37

Specifically, the mechanism explains the pattern. Delayed gastric emptying plus central appetite suppression produces early satiety, and early satiety plus a slowed transit produces exactly the symptom cluster people report.

Vomiting matters mostly through its consequences. Loss of gastric fluid depletes sodium, chloride and potassium, and hypokalaemia presents as exactly the fatigue and cramping people attribute to the drug. Persistent vomiting also makes a renal panel uninterpretable, because a pre-renal picture looks like renal impairment.

The gallbladder signal tracks the rate of weight loss more than it tracks the drug. Rapid mobilisation of adipose tissue increases biliary cholesterol saturation and reduces gallbladder motility; that combination is lithogenic whether the loss came from a drug, a very-low-energy diet or bariatric surgery. The drug contribution on top of that is present but smaller than the rate contribution.

I would flag that attributing a symptom to a drug is a hypothesis, and the base rate of these symptoms in the general population is high enough that the hypothesis is often wrong.

Fix the fixable causes first — fluid, electrolytes, sleep, intake — before concluding that the compound is responsible.

shareimprove this answerflag
EM
answeredeoin_mcgarry16k186 Oct 2025
6Do you have a reference for the last claim? Not disputing it, just want to read it. – eighty_six_hours 10 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.